Peppermint Venture Partners et al. back CAP-CMV

Peppermint Venture Partners invested via its new Charité Biomedical Fund. Additional investors include NRW.Bank, Creathor Venture, KfW as well as private investors.

The fresh capital will be used to advance CAP-CMV's novel vaccine candidate, which consists of HCMV-dense bodies, shed during cell infections.

The round provides the basis for a larger financing round in 2014 to advance the program into the clinical development stage.

Company
CAP-CMV is a spinout from CEVEC Pharmaceuticals, focusing exclusively on the development of a new vaccine protecting against human cytomegalovirus (HCMV) infection.

CAP-CMV was established as a joint project between CEVEC Pharmaceuticals, Vakzine Projekt Management and Prof. Plachter of the University Medical Center Mainz in 2013.

People
Joachim Rautter is a managing partner at PVP. Wolfgang Kintzel is CEO of CAP-CMV.

 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Now researching
• Germany